Cancer associated retinopathy

Last updated
Cancer Associated Retinopathy
Specialty Ophthalmology, optometry
Complications Blindness [1]
Diagnostic method Eye examination
Differential diagnosis Retinitis pigmentosa
TreatmentImmunosuppression

Cancer Associated Retinopathy (CAR) also known as Carcinoma Associated Retinopathy is an immune-mediated disease affecting the retina of the eye. It is a paraneoplastic type autoimmune retinopathy associated with cancer that can cause blindness. It can be seen in association with various types of cancers. It can be treated with a combination of chemotherapy and immunosuppression.

Contents

Pathophysiology

It is a paraneoplastic type of autoimmune retinopathy. [2] It may be seen in association with various cancers including non-small cell lung cancer, breast cancer, gynacological cancers, tumors of the hematopoietic and lymphoid tissues, basal cell carcinoma, colon cancer, kidney cancer, prostate cancer and pancreatic cancer. [1]

CAR results from the interaction between retinal antigen expression in cancer tissues and their systemic immune response. These antigens trigger an autoimmune response within the host to form antibodies that cross-react with the retinal antigen. This ultimately leads to retinal degeneration and apoptosis. Recoverin is the most common antigen associated with CAR. [3]

Prevalence

The prevalence of CAR among cancer patients is thought to be 10%–15%. [4]

Signs and symptoms

Patients may complain loss of vision, black spots in the field of vision (scotoma), night blindness, prolonged glare after light exposure, prolonged dark adaptation and defects in colour vision (dyschromatopsia). [5] Major signs include circulating anti-retinal antibodies along with loss of the outer retinal layer including the ellipsoid layer and photoreceptor cells, abnormalities in ERG, fundus autofluorescence and visual field defectss. [5]

Diagnosis

CAR is suspected in cancer patients who present with unexplained visual loss, scotomas and an abnormal ERG. [6] Antiretinal antibodies can be detected using Western blot test, immunohistochemistry test or ELISA testing. But the diagnosis is challenging as the signs and symptoms overlaps with many other diseases affecting the retina. [7]

Treatment

Long-term systemic Immunosuppressive therapy is the main treatment of cancer-associated retinopathy. [5] It can be treated with a combination of chemotherapy and immunosuppression. [2] Although tumor removal and cancer regression may result in a decrease in circulating autoantibodies, this does not influence CAR progression. [8]

Systematic immunosuppressive medications used in the treatment include corticosteroids, cyclosporin, azathioprine and alemtuzumab. [5] Intravenous immunoglobulin injections have several advantages including neutralization of autoantibodies. [5] Various monoclonal antibodies are also used to treat CAR. [1]

History

In 1976, cancer-related vision loss and photoreceptor dysfunction were first described by Sawyer et al. [2]

Related Research Articles

<span class="mw-page-title-main">Retina</span> Part of the eye

The retina is the innermost, light-sensitive layer of tissue of the eye of most vertebrates and some molluscs. The optics of the eye create a focused two-dimensional image of the visual world on the retina, which then processes that image within the retina and sends nerve impulses along the optic nerve to the visual cortex to create visual perception. The retina serves a function which is in many ways analogous to that of the film or image sensor in a camera.

<span class="mw-page-title-main">Diabetic retinopathy</span> Medical condition

Diabetic retinopathy, is a medical condition in which damage occurs to the retina due to diabetes mellitus. It is a leading cause of blindness in developed countries.

<span class="mw-page-title-main">Retinitis pigmentosa</span> Gradual retinal degeneration leading to progressive sight loss

Retinitis pigmentosa (RP) is a genetic disorder of the eyes that causes loss of vision. Symptoms include trouble seeing at night and decreasing peripheral vision. As peripheral vision worsens, people may experience "tunnel vision". Complete blindness is uncommon. Onset of symptoms is generally gradual and often begins in childhood.

The National Eye Institute (NEI) is part of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NEI is "to eliminate vision loss and improve quality of life through vision research." NEI consists of two major branches for research: an extramural branch that funds studies outside NIH and an intramural branch that funds research on the NIH campus in Bethesda, Maryland. Most of the NEI budget funds extramural research.

<span class="mw-page-title-main">Electroretinography</span>

Electroretinography measures the electrical responses of various cell types in the retina, including the photoreceptors, inner retinal cells, and the ganglion cells. Electrodes are placed on the surface of the cornea or on the skin beneath the eye to measure retinal responses. Retinal pigment epithelium (RPE) responses are measured with an EOG test with skin-contact electrodes placed near the canthi. During a recording, the patient's eyes are exposed to standardized stimuli and the resulting signal is displayed showing the time course of the signal's amplitude (voltage). Signals are very small, and typically are measured in microvolts or nanovolts. The ERG is composed of electrical potentials contributed by different cell types within the retina, and the stimulus conditions can elicit stronger response from certain components.

Sudden acquired retinal degeneration syndrome (SARDS) is a disease in dogs causing sudden blindness. It can occur in any breed, but female dogs may be predisposed. Approximately 4000 cases are seen in the United States annually.

Paraneoplastic cerebellar degeneration (PCD) is a paraneoplastic syndrome associated with a broad variety of tumors including lung cancer, ovarian cancer, breast cancer, Hodgkin’s lymphoma and others. PCD is a rare condition that occurs in less than 1% of cancer patients.

<span class="mw-page-title-main">Optic pit</span> Medical condition

Optic pit, optic nerve pit, or optic disc pit (ODP) is rare a congenital excavation (or regional depression) of the optic disc (also optic nerve head), resulting from a malformation during development of the eye. The incidence of ODP is 1 in 10,000 people with no predilection for either gender. There is currently no known risk factors for their development. Optic pits are important because they are associated with posterior vitreous detachments (PVD) and even serous retinal detachments.

A paraneoplastic syndrome is a syndrome that is the consequence of a tumor in the body. It is specifically due to the production of chemical signaling molecules by tumor cells or by an immune response against the tumor. Unlike a mass effect, it is not due to the local presence of cancer cells.

<span class="mw-page-title-main">Anti-actin antibodies</span>

Anti-actin antibodies (AAA) are found at increased frequency in certain autoimmune diseases and may be of some diagnostic value.

<span class="mw-page-title-main">Macular telangiectasia</span> Disease of the retina affecting central vision

Macular telangiectasia is a condition of the retina, the light-sensing tissue at the back of the eye that causes gradual deterioration of central vision, interfering with tasks such as reading and driving.

Paraneoplastic pemphigus (PNP) is an autoimmune disorder stemming from an underlying tumor. It is hypothesized that antigens associated with the tumor trigger an immune response resulting in blistering of the skin and mucous membranes.

White dot syndromes are inflammatory diseases characterized by the presence of white dots on the fundus, the interior surface of the eye. The majority of individuals affected with white dot syndromes are younger than fifty years of age. Some symptoms include blurred vision and visual field loss. There are many theories for the etiology of white dot syndromes including infectious, viral, genetics and autoimmune.

Multiple evanescent white dot syndrome (MEWDS) is an uncommon inflammatory condition of the retina that typically affects otherwise healthy young females in the second to fourth decades of life.

<span class="mw-page-title-main">Autoimmune autonomic ganglionopathy</span> Medical condition

Autoimmune autonomic ganglionopathy is a type of immune-mediated autonomic failure that is associated with antibodies against the ganglionic nicotinic acetylcholine receptor present in sympathetic, parasympathetic, and enteric ganglia. Typical symptoms include gastrointestinal dysmotility, orthostatic hypotension, and tonic pupils. Many cases have a sudden onset, but others worsen over time, resembling degenerative forms of autonomic dysfunction. For milder cases, supportive treatment is used to manage symptoms. Plasma exchange, intravenous immunoglobulin, corticosteroids, or immunosuppression have been used successfully to treat more severe cases.

Autoimmune retinopathy (AIR) is a rare disease in which the patient's immune system attacks proteins in the retina, leading to loss of eyesight. The disease is poorly understood, but may be the result of cancer or cancer chemotherapy. The disease is an autoimmune condition characterized by vision loss, blind spots, and visual field abnormalities. It can be divided into cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR). The condition is associated with retinal degeneration caused by autoimmune antibodies recognizing retinal proteins as antigens and targeting them. AIR's prevalence is extremely rare, with CAR being more common than MAR. It is more commonly diagnosed in females in the age range of 50–60.

Photic retinopathy is damage to the eye's retina, particularly the macula, from prolonged exposure to solar radiation or other bright light, e.g., lasers or arc welders. The term includes solar, laser, and welder's retinopathy and is synonymous with retinal phototoxicity. It usually occurs due to staring at the Sun, watching a solar eclipse, or viewing an ultraviolet, Illuminant D65, or other bright light.[1]

Occult macular dystrophy (OMD) is a rare inherited degradation of the retina, characterized by progressive loss of function in the most sensitive part of the central retina (macula), the location of the highest concentration of light-sensitive cells (photoreceptors) but presenting no visible abnormality. "Occult" refers to the degradation in the fundus being difficult to discern. The disorder is called "dystrophy" instead of "degradation" to distinguish its genetic origin from other causes, such as age. OMD was first reported by Y. Miyake et al. in 1989.

Sickle cell retinopathy can be defined as retinal changes due to blood vessel damage in the eye of a person with a background of sickle cell disease. It can likely progress to loss of vision in late stages due to vitreous hemorrhage or retinal detachment. Sickle cell disease is a structural red blood cell disorder leading to consequences in multiple systems. It is characterized by chronic red blood cell destruction, vascular injury, and tissue ischemia causing damage to the brain, eyes, heart, lungs, kidneys, spleen, and musculoskeletal system.

Drug abuse retinopathy is damage to the retina of the eyes caused by chronic drug abuse. Types of retinopathy caused by drug abuse include maculopathy, Saturday night retinopathy, and talc retinopathy. Common symptoms include temporary and permanent vision loss, blurred vision, and night blindness. Substances commonly associated with this condition include poppers, heroin, cocaine, methamphetamine, tobacco, and alcohol.

References

  1. 1 2 3 Singh, Dheerendra; Tripathy, Koushik (2022), "Cancer Associated Retinopathy", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   35201711, archived from the original on 2023-11-07, retrieved 2023-02-16
  2. 1 2 3 Grange, Landon; Dalal, Monica; Nussenblatt, Robert B.; Sen, H. Nida (February 2014). "Autoimmune Retinopathy". American Journal of Ophthalmology. 157 (2): 266–272.e1. doi:10.1016/j.ajo.2013.09.019. ISSN   0002-9394. PMC   3946999 . PMID   24315290.
  3. Dy, Irene; Chintapatla, Rangaswamy; Preeshagul, Isabel; Becker, Daniel (2013-11-01). "Treatment of Cancer-Associated Retinopathy With Rituximab". Journal of the National Comprehensive Cancer Network. 11 (11): 1320–1324. doi:10.6004/jnccn.2013.0156. ISSN   1540-1405. PMID   24225966. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
  4. Dimitriou, Eleni; Chatzirallis, Alexandros; Katopodis, Sokratis; Theodossiadis, George; Theodossiadis, Panagiotis; Chatziralli, Irini (2021-05-01). "Cancer-associated retinopathy 4 years after surgery for ovarian cancer". Oman Journal of Ophthalmology. 14 (2): 108–111. doi: 10.4103/ojo.ojo_352_20 . ISSN   0974-620X. PMC   8300284 . PMID   34345145.
  5. 1 2 3 4 5 "Cancer Associated Retinopathy - EyeWiki". eyewiki.aao.org. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
  6. Goetgebuer, Griet; Kestelyn-Stevens, A.-M.; Laey, J.; Kestelyn, P.; Leroy, B. (2007). "Cancer-associated retinopathy (CAR) with electronegative ERG: a case report". Documenta Ophthalmologica. 116 (1): 49–55. doi:10.1007/s10633-007-9074-9. PMID   17721792. S2CID   9253958.
  7. "Diagnosis and Management of Autoimmune Retinopathy". American Academy of Ophthalmology. 2017-09-01. Archived from the original on 2023-02-16. Retrieved 2023-02-16.
  8. "Cancer associated retinopathy". Eye News. Archived from the original on 2023-02-16. Retrieved 2023-02-16.